Skip to main content

11-01-2022 | Medications | News

News in brief

Triple agonist shows early promise for type 2 diabetes

Author: Eleanor McDermid


medwireNews: A novel triple receptor agonist has demonstrated an acceptable safety profile and promising reductions in blood glucose and bodyweight in a phase 1b trial reported in The Lancet.

In common with tirzepatide, the novel medication, currently known as LY3437943, stimulates the receptors for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP)-1, but it is also a glucagon receptor agonist.

It “is less potent at the human glucagon and GLP-1 receptors compared with native glucagon and GLP-1, and more potent at human GIP compared with native GIP,” say Zvonko Milicevi (Eli Lilly and Company, Indianapolis, Indiana, USA) and co-researchers.

In this trial, LY3437943 was tested in 72 people with type 2 diabetes, given as subcutaneous injections at doses ranging from 0.5 to 12 mg/week, and compared with dulaglutide 1.5 mg (not titrated up from 0.75 mg) and placebo.

Its safety profile was “consistent” with those of “other incretin-based therapeutic agents in early phases of development,” say the investigators, with gastrointestinal complaints being the most common adverse effect.

The medication had a half-life of approximately 6 days, making it suitable for once-weekly dosing.

Moreover, participants taking LY3437943 had an average placebo-adjusted glycated hemoglobin reduction of up to 1.6% (17.1 mmol/mol) during 12 weeks of treatment and a placebo-adjusted bodyweight reduction of up to 8.96 kg.

“The findings suggest that simultaneous agonism on these three receptors is a therapeutic approach that has acceptable safety and tolerability across a range of doses administered over 12 weeks,” concludes the team.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

Lancet 2022; doi:10.1016/S0140-6736(22)02033-5


Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Related content